PAI were tested for the following indications: ASA in primary [28–35] and secondary prevention of cardiovascular disease (CVD) [36], ASA in the primary and secondary prevention of stroke in patients with and without AF [30, 34, 37–50]ADP-receptor inhibitors in secondary prevention of cardiovascular events [51, 52] and stroke/TIA [52–54], and dipyridamol in secondary prevention of stroke [55, 56]. Here, P2RY1 is linked to atrial fibrillation.